This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Example content




Information on adverse event reporting can be found at the bottom of this page.

​​​​​​​Committed To Improving The Lives Of Those Affected By Cancer

Pfizer Oncology has a longstanding commitment to the pursuit of life-changing breakthroughs. By placing patients and collaboration at the centre of everything we do, we believe we can have a meaningful impact on the lives of cancer patients. Both now, and in the future.

Changing Lives

Every day, around 1,000 people are diagnosed with cancer in the UK.But, thanks to innovative treatment breakthroughs and significant advances in our understanding of the disease, more people than ever are surviving cancer.2

At Pfizer Oncology, we have an industry-leading portfolio of more than 20 approved innovative cancer medicines and biosimilars across over 30 indications, including melanoma, breast, genitourinary, colorectal, blood and lung cancers.3

We've made meaningful progress - but our work is far from finished. Currently, there are 130 Pfizer-sponsored Oncology clinical trials, with studies spanning more than 20 different tumour types and subtypes.4​​​​​​​

Building Partnerships

At Pfizer UK, we are proud of our long history of successfully partnering with organisations that share our purpose to deliver the right treatment for each patient at the right time. We also partner with scientists, academics and clinicians, to share knowledge, skills and expertise, with the aim to improve the health and lives of people in the UK and around the world.

Over the past 70 years, we have continued to invest in the UK and are committed to working with the National Health Service (NHS) and other healthcare organisations across the industry, developing solutions to improve the delivery of care and patient outcomes. The NHS has access to over 150 Pfizer medicines and vaccines that are delivered to pharmacies, surgeries, and hospitals across the UK every day.5

We also partner with relevant policy-makers and other stakeholders driven by our purpose: ​​​​​​​Breakthroughs that change patients' lives.

​​​​​​​Empowering Patients

Patients are now -  more than ever - equipped, informed and empowered to define healthcare in their own terms. At Pfizer, we recognise the importance of harnessing the power of patient experiences to understand what healthcare means to the individual. Through our commitment to working together, we aim to personalise patient care and deliver better healthcare for the people that matter most - patients.6

Patient centricity within Pfizer Oncology is a longstanding tradition. Over the years, our team has cultivated relationships with many patient advocates across the world - with the common goals of ensuring health equity and literacy for all, and supporting patient engagement in clinical trials.

In 2019, to expand these efforts and further embed patient insights and experiences into all activities, Pfizer Oncology launched an initiative to create a Patient Centric Ecosystem (POPCE). Today, this ecosystem is continuing to yield actionable insights, providing opportunities for information-sharing and partnership across the cancer community.4

Committed To The Future

At Pfizer, we are relentless in our pursuit of medicines and vaccines that will benefit patients around the world, and our product pipeline has never been stronger. By 2025, we are committed to treating 225 million people with breakthrough therapies.

In addition to our medicines, we are also supporting patients through innovative technologies, such as the ByYourSideTM app, a digital support programme designed specifically to help people living with cancer, as well as their friends and family members.7 

In the UK, our investment goes beyond our medicines. We are investing in the future by supporting the scientists of tomorrow, through the UK's National Apprenticeship Programme, our undergraduate placement scheme and various STEM (Science, Technology, Engineering and Mathematics) and SIP (Science Industry Partnership) activities.​​​​​​​5


1. Cancer Research UK. Cancer incidence statistics. Available at: [Last accessed: May 2022].
2. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107 (7):1195-202.
3. Pfizer press release. Pfizer Completes Acquisition of Trillium Therapeutics. November 2021. Available at: [Last accessed May 2022].
4. Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact. Available at: [Last accessed: May 2022].
5. Pfizer in the UK. April 2022. Available at: [Last accessed: May 2022].
6. Pfizer press release. Working with Patient Organisations. Available at: [Last accessed: May 2022].
7. Pfizer press release. ByYourSide App and Website launched to help cancer patients in need. Available at: [Last accessed: May 2022]

PP-UNP-GBR-0756. May 2022

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

​​​​​​I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

​​​​​​​*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.​​​​​​​

​​​​​​​PP-PFE-GBR-3863. November 2021​​​​​​

Yes No
You are now leaving PfizerPro  
​​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
You are now leaving PfizerPro  
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021​​​​​​​

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?